The charitable American Trauma Brain Foundation has assembled and financed an expert task force to suggest guidelines for the management of patients with severe head injury (Glasgow coma score of 3-8 on presentation). They have addressed the concern that the clinical practise for these patients is diverse.' The task force selected 14 topics considered central to optimal care of head injury, and used a systematic process of review to gather the available evidence. After critical analysis of selected publications, recommendations were put forward, and the degree of clinical certainty which accompanied the evidence for each topic was emphasised. Successive versions of the guidelines have been reported to the American Association of Neurological Surgeons and other North American medical societies, inviting detailed criticism. The suggested guidelines were also presented to a consortium of European neurosurgeons with expertise in neurotrauma for peer review. As new evidence becomes available, they anticipate that the recommendations will be updated in later editions.
The process of evaluating the scientific evidence was largely restricted to information obtained by means of Medline. Publications dating back to 1966 were searched using targeted keywords. References obtained in this way were assessed for suitability of design, content and relevance. A high proportion of these were subsequently rejected. Of those publications deemed suitable, a summary and a conclusion were provided under each topic heading. The process adopted would have identified most of the important studies, but a significant wealth of information may have been missed from non-English cultures, such as that in the Japanese literature. An extended systematic review of the literature, such as that recommended by the Cochrane Collaboration,2 was not undertaken. Although the international experience of the task force will compensate for this, the exclusion of such data may affect the acceptance of the guidelines in some countries. However, now that the framework for update has been established, it is envisaged that future studies from diverse international sources can be reviewed and included with relative ease.
The problems encountered in providing evidence for clinical guidelines in severe head injury are well known to those managing these patients. A detailed account of these difficulties is comprehensively stated by the authors in the introduction. The process of review and critical analysis (specifically avoiding personal opinion) led the task force to consider the available evidence of insufficient clinical head injury certainty to provide "standards" for 11 of the 14 topics reviewed (table) . This is a distinctive feature of the document which recurrently highlights the lack of quality data available for key issues in management of head injury. Thus class I data (prospective randomised controlled trials) necessary for setting standards is generally not available. Rather, "guidelines" with a moderate degree of clinical certainty from class II data (high quality prospective and retrospective data), and "options" based on information with unclear clinical certainty (class III data), are offered.
Centralisation of effort into recognised head injury units which have expertise in the intensive care management of these patients is central to the task force's conclusions. Guidelines are only of use if they can be implemented in a competent and reliable way by specialist personnel who have an interest in treating this difficult condition. Receiving suitably resuscitated head injured patients in a timely fashion is dependent on highly organised trauma services, and access to 24 hour advanced trauma life support (ATLS) evaluation. Realistically, this can only be implemented within designated trauma units with on site neurosurgical support, and the supporting evidence has encouraged the task force to promote the provision for trauma centres as a guideline.
The task force have been confident in providing standards for three topics. Carefully conducted randomised trials show that steroid therapy is of no efficacy and is not recommended (topic 1 1, table). Although anticonvulsants reduce the incidence of early post-traumatic seizures, they do not seem to reduce the occurrence of late post-traumatic seizures (topic 14; table 1), hence long term prophylactic treatment is not recommended. Thirdly, the data detailing the case against prolonged hyperventilation in the absence of raised intracranial pressure has been considered sufficient to provide a standard (topic 8, table). Prolonged hyperventilation causing profound cerebral vasoconstriction and secondary cerebral ischaemia should be avoided. However, acknowledgement is made that controlled hyperventilation can still be used to reduce persistent intracranial hypertension provided cerebral oxygenation is monitored carefully.3
The class II evidence for promoting resuscitation to correct hypoxia and hypotension in those with severe head injury is overwhelming. Despite this, the task force considered that they could not issue standards for the precise threshold of arterial blood pressure and blood oxygenation. As there is a universal agreement that a randomised In summary, the document initiated by the American Trauma Brain Foundation provides a welcomed comprehensive review of modem management of head injury. The systematic and non-bias analytical approach has highlighted the paucity of high quality published data allowing standards to be set. Nevertheless, rather than dismiss the available evidence, the task force has debated the issues and generated guidelines, and in doing so they have provided a basic database which allows for future update. It is not the intention of the participants to standardise care of head injury throughout the world, a difficult task given the great heterogeneity in the geographical, resource related, and pathophysiological variables operating in different head injury units. However, without such standardisation, it is difficult to envisage how multicentre randomised trials can ever achieve sufficient power to prove efficacy for a given therapy. 
